KRT19 and cancer: Although down‐regulated by in vitro TGF‐β treatment, CK19 was still highly expressed and easily detectable in cancer cells (Appendix Fig S5B), which enabled the in vivo identification of cancer cells with partial EMT phenotype in metastatic sites.